Skip to main
GMAB

GMAB Stock Forecast & Price Target

GMAB Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Genmab is well-positioned to continue its strong financial performance based on its impressive pipeline of cancer therapeutics and partnerships with major pharmaceutical companies. Its latest financial results showed solid revenue and earnings, and the company has issued positive guidance for 2026. With a strong balance sheet and a track record of profitability, Genmab is well-equipped to weather potential challenges in the biotech sector, making it an attractive stock for investors. However, there are risks to consider, such as the potential for slowing DARZALEX sales and negative outcomes from clinical trials, which could impact the company's financial performance.

Bears say

Genmab is currently highly reliant on their partnership with Johnson & Johnson for their leading product Darzalex, as well as other partnerships for their pipeline candidates. The recent positive top-line results for ELREXFIO, a competitor to Darzalex, may pose a threat to Genmab's market share and could lead to a slowdown in sales. Furthermore, the company faces risks such as potential label extension failures, lower-than-expected product penetration, and possible failures of other agents in clinical testing, which could impact their future financial performance.

GMAB has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Genmab - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Genmab - ADR (GMAB) Forecast

Analysts have given GMAB a Buy based on their latest research and market trends.

According to 7 analysts, GMAB has a Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $39.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $39.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Genmab - ADR (GMAB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.